PMID- 37920417
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231104
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Print)
IS  - 2049-9450 (Linking)
VI  - 19
IP  - 6
DP  - 2023 Dec
TI  - Altered expression of imprinted genes in patients with cytogenetically 
      normal‑acute myeloid leukemia: Implications for leukemogenesis and survival 
      outcomes.
PG  - 94
LID - 10.3892/mco.2023.2690 [doi]
LID - 94
AB  - Genomic imprinting, an epigenetic mechanism that regulates gene expression from 
      parental chromosomes, holds substantial relevance in multiple cancers, including 
      hematopoietic malignancies. In the present study, the expression of a panel of 16 
      human imprinted genes in bone marrow samples from 64 patients newly diagnosed 
      with cytogenetically normal-acute myeloid leukemia (CN-AML) were examined 
      alongside peripheral blood samples from 85 healthy subjects. The validated 
      findings of the present study revealed significant upregulation of seven genes 
      [COPI coat complex subunit gamma 2 (COPG2), H19 imprinted maternally expressed 
      transcript (H19), insulin like growth factor 2 (IGF2), PEG3 antisense RNA 1 
      (PEG3-AS1), DNA primase subunit 2 (PRIM2), solute carrier family 22 member 3 
      SLC22A3 and Zinc finger protein 215 (ZNF215)] in patients with CN-AML (P<0.001). 
      Notably, the expression level of H19 exhibited an inverse association with the 
      survival duration of the patients (P=0.018), establishing it as a predictive 
      marker for two- and five-year survival in patients with CN-AML. Kaplan-Meier 
      analysis demonstrated that patients with lower H19 expression had superior two- 
      and five-year survival rates compared with those with higher H19 expression. The 
      results of the present study highlighted the association between loss of 
      imprinting and leukemogenesis in CN-AML, underscoring the significance of H19 
      imprinting loss as a prognostic indicator for unfavorable two- and five-year 
      survival in CN-AML patients.
CI  - Copyright: (c) Yang et al.
FAU - Yang, Ming-Yu
AU  - Yang MY
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, Taoyuan 33302, Taiwan, R.O.C.
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Taiwan 83301, Taiwan, R.O.C.
FAU - Hsu, Cheng-Ming
AU  - Hsu CM
AD  - Department of Otolaryngology-Head and Neck Surgery, Chiayi Chang Gung Memorial 
      Hospital, Puzi, Chiayi 61363, Taiwan, R.O.C.
AD  - Department of Medicine, College of Medicine, Chang Gung University, Taoyuan 
      33302, Taiwan, R.O.C.
FAU - Lin, Pai-Mei
AU  - Lin PM
AD  - School of Medicine for International Students and Department of Nursing, I-Shou 
      University, Kaohsiung 82445, Taiwan, R.O.C.
FAU - Yang, Chao-Hui
AU  - Yang CH
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, Taoyuan 33302, Taiwan, R.O.C.
AD  - Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang 
      Gung University College of Medicine, Taiwan 83301, Taiwan, R.O.C.
FAU - Hu, Ming-Luen
AU  - Hu ML
AD  - Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 
      Taiwan 83302, Taiwan, R.O.C.
FAU - Chen, I-Ya
AU  - Chen IY
AD  - Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung 
      University, Taoyuan 33302, Taiwan, R.O.C.
FAU - Lin, Sheng-Fung
AU  - Lin SF
AD  - Division of Hematology and Oncology, Department of Internal Medicine, E-Da 
      Hospital, Kaohsiung 82445, Taiwan, R.O.C.
LA  - eng
PT  - Journal Article
DEP - 20231005
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC10619196
OTO - NOTNLM
OT  - H19 gene
OT  - cytogenetically normal-acute myeloid leukemia
OT  - five-year survival
OT  - imprinted genes
OT  - two-year survival
COIS- The authors declare that they have no competing interests.
EDAT- 2023/11/03 06:44
MHDA- 2023/11/03 06:45
PMCR- 2023/10/05
CRDT- 2023/11/03 03:55
PHST- 2023/06/15 00:00 [received]
PHST- 2023/09/21 00:00 [accepted]
PHST- 2023/11/03 06:45 [medline]
PHST- 2023/11/03 06:44 [pubmed]
PHST- 2023/11/03 03:55 [entrez]
PHST- 2023/10/05 00:00 [pmc-release]
AID - MCO-19-6-02690 [pii]
AID - 10.3892/mco.2023.2690 [doi]
PST - epublish
SO  - Mol Clin Oncol. 2023 Oct 5;19(6):94. doi: 10.3892/mco.2023.2690. eCollection 2023 
      Dec.